MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.940
-0.130
-6.28%
After Hours: 2.000 +0.06 +3.09% 19:37 03/03 EST
OPEN
2.090
PREV CLOSE
2.070
HIGH
2.120
LOW
1.940
VOLUME
741.28K
TURNOVER
--
52 WEEK HIGH
9.67
52 WEEK LOW
1.260
MARKET CAP
36.86M
P/E (TTM)
-0.8039
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Millendo Therapeutics Inc - On Jan 22, Board Approved Corporate Restructuring Plan
reuters.com · 01/28 17:25
Millendo discloses restructuring plan to cut up to 85% of its workforce
Millendo Therapeutics ([[MLND]] +1.6%) announces board approval for a corporate restructuring plan which will result in an up to 85% reduction in the company's workforce.The company said that majority of the
Seekingalpha · 01/28 16:14
Millendo Therapeutics shares drop after pulling plug on MLE-301 development
Based on an analysis of data from the ongoing Phase 1 study evaluating Millendo Therapeutics' ([[MLND]] -18.7%) MLE-301 for menopausal vasomotor symptoms, the board of directors have decided to discontinue
Seekingalpha · 01/05 20:16
SYN, TRXC, JAGX and BNGO among midday movers
Gainers: Synthetic Biologics (SYN) +141%.Helius Medical Technologies (HSDT) +91%.The Peck Company (PECK) +79%.Atomera (ATOM) +50%.Check-Cap (CHEK) +49%.Naked Brand Group (NAKD) +42%.The9 (NCTY) +37%.Gritstone Oncology (GRTS) +36%.Boston Private Financial (BPFH) +31%.Jaguar Health (JAGX) +20%.Losers: Mersana
Seekingalpha · 01/05 17:42
Synthetic Biologics, Check-Cap leads healthcare gainers; Bionano Genomics, Mersana Therapeutics among major losers
Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics (MLND) -18%, TransEnterix (TRXC) -17%, Hoth Therapeutics HOTH -12%.
Seekingalpha · 01/05 16:05
Mid-Morning Market Update: Markets Edge Higher; ISM Manufacturing PMI Jumps to 60.7
Following the market opening Tuesday, the Dow traded up 0.09% to 30,252.40 while the NASDAQ rose 0.36% to 12,744.18. The S&P also rose, gaining 0.21% to 3,708.42.
Benzinga · 01/05 15:27
Millendo Therapeutics Provides Pipeline and Business Update
Business Wire · 01/05 14:00
Millendo Therapeutics Provides Pipeline and Business Update
Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.
Business Wire · 01/05 14:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MLND. Analyze the recent business situations of Millendo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MLND stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 7.94M
% Owned: 41.79%
Shares Outstanding: 19.00M
TypeInstitutionsShares
Increased
12
522.10K
New
14
350.72K
Decreased
13
1.10M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Executive Director
Julia Owens
President/Chief Executive Officer
Louis Arcudi
Chief Financial Officer/Chief Accounting Officer
Jennifer Minai-azary
General Counsel/Secretary
Tamara Joseph
Other
Christophe Arbet-Engels
Other
Thomas Hoover
Other
Ryan Zeidan
Director
Carol Gallagher
Independent Director
James Hindman
Independent Director
John Howe
Independent Director
Geoffrey Nichol
Independent Director
Carole Nuechterlein
  • Dividends
  • Splits
  • Insider Activity
No Data
About MLND
Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.

Webull offers kinds of Millendo Therapeutics Inc stock information, including NASDAQ:MLND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MLND stock methods without spending real money on the virtual paper trading platform.